Affimed N.V. (AFMD) announced on Tuesday the latest clinical outcomes of the ongoing AFM24-102 trial, which is assessing the effectiveness of the AFM24 and atezolizumab combination therapy in patients with non-small cell lung cancer (NSCLC) who have undergone extensive prior treatments.
In the NSCLC group with EGFR wild-type, the combination therapy achieved an overall response rate of 21% and a disease control rate of 76%. Notably, tumors were reduced in size for 48% of the 33 patients involved.
Conversely, in NSCLC patients with EGFR mutations, the therapy resulted in an overall response rate of 24% and a disease control rate of 71%. Tumor reduction was observed in 41% of the participants.
Furthermore, the company shared insights from a post-hoc exposure-response analysis involving patients administered with 480 mg of AFM24. The analysis revealed that higher exposure to AFM24 correlates with significantly enhanced response rates, as well as improved progression-free survival and overall survival.
Based on these results, the company intends to advance the future development of AFM24 using a 720 mg weekly dosage of the combination.
In pre-market trading, shares of Affimed experienced a decline of 6.10%, dropping to $2.00 on the Nasdaq.
The material has been provided by InstaForex Company - www.instaforex.com
In the NSCLC group with EGFR wild-type, the combination therapy achieved an overall response rate of 21% and a disease control rate of 76%. Notably, tumors were reduced in size for 48% of the 33 patients involved.
Conversely, in NSCLC patients with EGFR mutations, the therapy resulted in an overall response rate of 24% and a disease control rate of 71%. Tumor reduction was observed in 41% of the participants.
Furthermore, the company shared insights from a post-hoc exposure-response analysis involving patients administered with 480 mg of AFM24. The analysis revealed that higher exposure to AFM24 correlates with significantly enhanced response rates, as well as improved progression-free survival and overall survival.
Based on these results, the company intends to advance the future development of AFM24 using a 720 mg weekly dosage of the combination.
In pre-market trading, shares of Affimed experienced a decline of 6.10%, dropping to $2.00 on the Nasdaq.
The material has been provided by InstaForex Company - www.instaforex.com